X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (306) 306
humans (303) 303
oncology (286) 286
female (276) 276
middle aged (244) 244
aged (220) 220
adult (214) 214
chemotherapy (149) 149
male (143) 143
cancer (123) 123
breast cancer (117) 117
prognosis (105) 105
antineoplastic combined chemotherapy protocols - therapeutic use (87) 87
aged, 80 and over (80) 80
treatment outcome (78) 78
breast neoplasms - drug therapy (72) 72
disease-free survival (66) 66
research (66) 66
breast neoplasms - pathology (62) 62
survival analysis (60) 60
neoplasm staging (59) 59
survival (57) 57
carcinoma (56) 56
immunohistochemistry (52) 52
paclitaxel (50) 50
analysis (48) 48
research article (47) 47
breast neoplasms - mortality (46) 46
retrospective studies (46) 46
therapy (46) 46
care and treatment (45) 45
chemotherapy, adjuvant (44) 44
metastasis (44) 44
medical research (43) 43
medicine (42) 42
medicine & public health (42) 42
genetic aspects (41) 41
tumors (41) 41
clinical trials (40) 40
survival rate (40) 40
mutation (39) 39
antineoplastic combined chemotherapy protocols - adverse effects (38) 38
breast neoplasms - genetics (38) 38
drug administration schedule (38) 38
young adult (38) 38
patients (37) 37
gene expression (36) 36
radiotherapy (35) 35
expression (33) 33
neoplasm metastasis (33) 33
paclitaxel - administration & dosage (33) 33
antineoplastic agents - therapeutic use (32) 32
cisplatin (32) 32
combined modality therapy (32) 32
genetics (32) 32
trial (32) 32
drug therapy (31) 31
health aspects (31) 31
kaplan-meier estimate (31) 31
multivariate analysis (31) 31
pathology (31) 31
risk factors (31) 31
colorectal cancer (30) 30
hospitals (30) 30
cancer research (29) 29
cancer therapies (29) 29
carboplatin (29) 29
fluorouracil - administration & dosage (29) 29
antineoplastic combined chemotherapy protocols - administration & dosage (28) 28
carboplatin - administration & dosage (28) 28
follow-up studies (28) 28
ovarian cancer (28) 28
breast-cancer (27) 27
epirubicin (27) 27
greece (27) 27
adjuvant chemotherapy (26) 26
breast neoplasms - metabolism (26) 26
cancer patients (26) 26
hematology, oncology and palliative medicine (26) 26
oncology, experimental (26) 26
proportional hazards models (25) 25
trastuzumab (25) 25
studies (24) 24
genes (23) 23
biomarkers, tumor - genetics (22) 22
gene expression regulation, neoplastic (22) 22
medical prognosis (22) 22
risk (22) 22
biomarkers (21) 21
biomarkers, tumor - metabolism (21) 21
erbb-2 protein (21) 21
multidisciplinary sciences (21) 21
patient outcomes (21) 21
receptor, erbb-2 - metabolism (21) 21
abridged index medicus (20) 20
anthracyclines (20) 20
cisplatin - administration & dosage (20) 20
colorectal neoplasms - drug therapy (20) 20
head and neck neoplasms - drug therapy (20) 20
medical and health sciences (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 06/2012, Volume 12, Issue 1, pp. 271 - 271
Background: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal... 
Irinotecan | Chemotherapy | Capecitabine | Angiogenic markers | Colorectal cancer | Bevacizumab | COLON-CANCER | OSTEOPONTIN | ONCOLOGY | NITRIC-OXIDE | ORAL FLUOROPYRIMIDINES | BICC-C | EXPRESSION | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Osteopontin - blood | Leucovorin - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Biomarkers - blood | Angiogenic Proteins - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Care and treatment | Patient outcomes | Research | Comparative analysis | Cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Nitric oxide | Product development | Vascular endothelial growth factor | Growth factors | Index Medicus
Journal Article
Journal Article
BMC Medicine, ISSN 1741-7015, 01/2011, Volume 9, Issue 1, pp. 10 - 10
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to... 
1ST-LINE TREATMENT | PLUS LEUCOVORIN | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | PERSPECTIVES | CAMPTOTHECINS | OXALIPLATIN | METASTATIC COLORECTAL-CANCER | FOLFIRI | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Greece | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Chemotherapy | Usage | Colon cancer | Patient outcomes | Leucovorin | Drug therapy, Combination | Drug therapy | Health aspects | Fluorouracil | Cancer | Medical imaging | Heart attacks | Statistical analysis | Mortality | Colorectal cancer | Clinical trials | Histology | Cancer therapies | Manuscripts | Medicine | Hospitals | Tomography | Clinical medicine | Acquisitions & mergers | Index Medicus
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 5/2014, Volume 140, Issue 5, pp. 737 - 748
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, pp. e0180489 - e0180489
Background-Aim To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various... 
OVEREXPRESSION | COOPERATIVE ONCOLOGY GROUP | PROGNOSTIC-FACTOR | EPIRUBICIN | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | DENSE SEQUENTIAL CHEMOTHERAPY | INHIBITORS | P21 | P27(KIP1) | Immunohistochemistry | Prognosis | Cyclin-Dependent Kinase Inhibitor p27 - analysis | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Young Adult | Cyclin D1 - analysis | Tumor Suppressor Protein p53 - analysis | Cyclin-Dependent Kinase Inhibitor p21 - analysis | Breast - drug effects | Breast Neoplasms - pathology | Triple Negative Breast Neoplasms - diagnosis | Cyclin E - analysis | Survival Analysis | Triple Negative Breast Neoplasms - pathology | Adult | Female | Aged | Breast Neoplasms - diagnosis | Oncogene Proteins - analysis | Breast - pathology | Usage | Analysis | Cell cycle | Clinical trials | Breast cancer | Research | Health sciences | GTP-binding protein | Regulators | Laboratories | Molecular clusters | p53 Protein | Oncology | Paraffin | Cyclin D1 | Kinases | Tissues | Cancer therapies | Formaldehyde | Cell adhesion & migration | Proteins | Medical research | Cyclin-dependent kinases | Clustering | Medicine | Pathology | Cyclin-dependent kinase inhibitor p21 | Hospitals | Medical prognosis | Breast | Tumors | Cancer | Apoptosis | Index Medicus
Journal Article
BMC Cancer, ISSN 1471-2407, 02/2013, Volume 13, Issue 1, pp. 49 - 49
Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis... 
PI3K gene mutations | Biomarkers | EGFR ligands | BRAF | KRAS | Cetuximab | Epidermal growth factor receptor | 1ST-LINE TREATMENT | LEUCOVORIN | EPIREGULIN | STATISTICS | FLUOROURACIL | CHEMOTHERAPY | BREAST-CANCER | PANITUMUMAB | MUTATION STATUS | ONCOLOGY | Colorectal Neoplasms - genetics | Humans | Middle Aged | Glycoproteins - metabolism | Male | Antineoplastic Agents - therapeutic use | Epiregulin | Amphiregulin | RNA, Messenger - metabolism | Intercellular Signaling Peptides and Proteins - metabolism | Receptor, Epidermal Growth Factor - metabolism | Adenocarcinoma - metabolism | EGF Family of Proteins | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Colorectal Neoplasms - metabolism | Genes, ras - genetics | Genetic Predisposition to Disease | Antibodies, Monoclonal, Humanized - therapeutic use | Epidermal Growth Factor - metabolism | Genotype | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Phosphatidylinositol 3-Kinase - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - secondary | Aged | Drugs | Adverse and side effects | Research | Drug therapy | Patient outcomes | Colorectal cancer | Medical research | Care and treatment | Genes | Metastasis | Antineoplastic agents | Formaldehyde | Antimitotic agents | Messenger RNA | Epidermal growth factor | Codon | Gene mutations | Analysis | Monoclonal antibodies | Medicine, Experimental | Genetic aspects | Biological markers | Health aspects | Index Medicus
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2016, Volume 158, Issue 2, pp. 307 - 321
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 8, pp. 753 - 762
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 645 - 655
Journal Article
BMC Cancer, ISSN 1471-2407, 05/2013, Volume 13, Issue 1, pp. 263 - 263
Background: Metronomic chemotherapy is considered an anti-angiogenic therapy that involves chronic administration of low-dose chemotherapy at regular short... 
Metronomic-chemotherapy | Antiangiogenic | Vinorelbine | Cancer | ANGIOGENESIS | CYCLOPHOSPHAMIDE | GROUP HECOG | RECEPTOR | TOXICITY | CHEMOTHERAPY | THERAPY | ONCOLOGY | RESISTANCE | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Liver Neoplasms - mortality | Dose-Response Relationship, Drug | Young Adult | Antineoplastic Agents, Phytogenic - administration & dosage | Vinblastine - analogs & derivatives | Biomarkers, Tumor - metabolism | Adult | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Real-Time Polymerase Chain Reaction | Prostatic Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Prostatic Neoplasms - pathology | Enzyme-Linked Immunosorbent Assay | Time-to-Treatment | Administration, Oral | RNA, Messenger - genetics | Translational Medical Research | Liver Neoplasms - drug therapy | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Prostatic Neoplasms - mortality | Breast Neoplasms - pathology | Adolescent | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Drug therapy | Metastasis | Research | Care and treatment | Cancer patients | Chemotherapy | Oncology, Experimental | Fibroblast growth factors | Lung cancer, Non-small cell | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, pp. e0207707 - e0207707
Journal Article